Results 21 to 30 of about 231,717 (193)

Assessment of transthyretin instability in patients with wild-type transthyretin amyloid cardiomyopathy

Scientific Reports
The pathophysiology of variant transthyretin (TTR) amyloidosis (ATTRv) is associated with destabilizing mutations in the TTR tetramer. However, why TTR with a wild-type genetic sequence misfolds and aggregates in wild-type transthyretin amyloidosis ...
Takuya Iino, Manabu Nagao, Hidekazu Tanaka, Sachiko Yoshikawa, Junko Asakura, Makoto Nishimori, Masakazu Shinohara, Amane Harada, Shunsuke Watanabe, Tatsuro Ishida, Ken-ichi Hirata, Ryuji Toh   +11 more
doaj   +2 more sources

Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy

Cardiology and Therapy
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease caused by the deposition of insoluble amyloid fibrils derived from misfolded transthyretin (TTR).
Emily Margolin, Lily K. Stern, Alessia Argiro, Julie L. Rosenthal, Marcus A. Urey, Kevin M. Alexander   +5 more
doaj   +2 more sources

Systemic embolism in amyloid transthyretin cardiomyopathy

European Journal of Heart Failure, 2022
Aims Although systemic embolism is a potential complication in transthyretin amyloid cardiomyopathy (ATTR‐CM), data about its incidence and prevalence are scarce. We studied the incidence, prevalence and factors associated with embolic events in ATTR‐CM.
Vilches, Silvia, Fontana, Marianna, Gonzalez‐Lopez, Esther, Mitrani, Lindsey, Saturi, Giulia, Renju, Mary, Griffin, Jan M., Caponetti, Angelo, Gnanasampanthan, Sahana, De los Santos, Jeffeny, Gagliardi, Christian, Rivas, Adrian, Dominguez, Fernando, Longhi, Simone, Rapezzi, Claudio, Maurer, Mathew S., Gillmore, Julian, Garcia‐Pavia, Pablo   +17 more
openaire   +9 more sources

A review of transthyretin cardiac amyloidosis

Romanian Journal of Internal Medicine, 2023
Transthyretin cardiac amyloidosis is a progressive disease known to cause heart failure, conduction anomalies, and arrythmias. Due to poor outcomes and mortality from severe cardiomyopathy, prevalence and incident rates are often underreported. As global
Jhawar Nikita, Moreno Juan Carlos Leoni, Chirila Razvan   +2 more
doaj   +1 more source

Wild-Type Transthyretin Cardiac Amyloidosis in a Transplanted Heart

JACC: Case Reports, 2023
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is more prevalent than appreciated in the elderly. We present the case of an 88-year-old woman who underwent heart transplantation for ischemic cardiomyopathy and then presented 21 years later ...
Lily K. Stern, MD, Pamela A. Ivey, MD, Corey J. Lum, DO, Shayaan Zaidi, Daniel Luthringer, MD, Angela Velleca, BSN, CCTC, Jon A. Kobashigawa, MD, Jignesh K. Patel, MD, PhD, Michelle M. Kittleson, MD, PhD   +8 more
doaj   +1 more source

Tafamidis in transthyretin amyloid cardiomyopathy [PDF]

Clinical pharmacology and therapy, 2021
Transthyretin is primarily synthesized in the liver and transports thyroxine and vitamin A in the body. The transthyretin when dissociated into monomers can misfold and ultimately form amyloid fibrils. There are two types of ATTR amyloidosis: hereditary (caused by mutations in the TTR gene) and wild-type (also referred to as senile systemic amyloidosis)
S. Moiseev, V. Rameev
openaire   +1 more source

Inotersen therapy of transthyretin amyloid cardiomyopathy [PDF]

Amyloid, 2019
Background: Cardiomyopathy is a major cause of death in patients with systemic transthyretin amyloidosis. Long term effect of therapy designed to inhibit hepatic production of the amyloid precursor has not been established in cardiomyopathy. The purpose of this study was to evaluate the long term safety and efficacy of transthyretin specific antisense ...
Noel R, Dasgupta, Stacy M, Rissing, Jessica, Smith, Jeesun, Jung, Merrill D, Benson   +4 more
openaire   +2 more sources

Transthyretin cardiac amyloidosis: an under-diagnosed cause of heart failure [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2014
Introduction: Cardiac amyloidosis is the most common cause of infiltrative cardiomyopathy and is associated with a poor prognosis. Transthyretin cardiac amyloidosis, particularly the type caused by the mutation that replaces the amino acid valine with ...
Gabriela Molina O, Daniel Judge, Wayne Campbell, Harjit Chahal, Marc Mugmon   +4 more
doaj   +1 more source

Transthyretin amyloid cardiomyopathy

Ugeskrift for Læger
Transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark.
Sie Kronborg, Fensman, Ale Hussein Jaber, Mejren, Tor Skibsted, Clemmensen, Steen Hvitfeldt, Poulsen   +3 more
  +8 more sources

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Whelan, CJ, Lachmann, HJ, Gillmore, JD, Gibbs, SD, Hawkins, PN, McCarthy, CA, Sattianayagam, P, Rowczenio, D, Wechalekar, A, Venner, CP, Petrie, A, Dungu, J, Wassef, N, Pinney, JH, Gilbertson, JA   +15 more
core   +1 more source